Penn Capital Management Company LLC Sells 21,128 Shares of RadNet, Inc. $RDNT

Key Points

• Penn Capital Management cut its RadNet stake by 7.8%, selling 21,128 shares, but still held 250,224 shares valued at about $17.3 million at the filing date.
• RadNet reported quarterly EPS of $0.30, beating estimates of $0.22, while revenue grew 22.1% year over year to $638.26 million—slightly below consensus.
• Analysts’ consensus rating was Buy, with a $90 price target; RadNet also raised its 2026 revenue outlook to $2.5 billion–$2.6 billion.

Penn Capital Management Company LLC reduced its stake in RadNet, Inc. (NASDAQ:RDNT - Free Report) by 7.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 250,224 shares of the medical research company's stock after selling 21,128 shares during the period. RadNet comprises 1.3% of Penn Capital Management Company LLC's investment portfolio, making the stock its 29th largest position. Penn Capital Management Company LLC owned 0.32% of RadNet worth $17,282,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently bought and sold shares of RDNT. Farther Finance Advisors LLC boosted its stake in shares of RadNet by 60.2% during the third quarter. Farther Finance Advisors LLC now owns 596 shares of the medical research company's stock valued at $41,000 after purchasing an additional 224 shares during the period. Parallel Advisors LLC increased its stake in shares of RadNet by 80.0% in the first quarter. Parallel Advisors LLC now owns 1,114 shares of the medical research company's stock worth $62,000 after buying an additional 495 shares during the period. GAMMA Investing LLC increased its stake in shares of RadNet by 10.6% in the third quarter. GAMMA Investing LLC now owns 2,321 shares of the medical research company's stock worth $160,000 after buying an additional 222 shares during the period. Nykredit A S purchased a new position in shares of RadNet in the second quarter worth $153,000. Finally, Modera Wealth Management LLC bought a new stake in RadNet during the 3rd quarter valued at $207,000. Institutional investors own 77.90% of the company's stock.

RadNet Price Performance

Shares of RDNT stock opened at $78.38 on Tuesday. The firm has a market cap of $6.17 billion, a P/E ratio of 182.41 and a beta of 1.42. RadNet, Inc. has a fifty-two week low of $50.82 and a fifty-two week high of $85.84. The business's 50 day moving average price is $72.64 and its 200-day moving average price is $65.43. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.48.

RadNet (NASDAQ:RDNT - Get Free Report) last announced its earnings results on Sunday, November 8th. The medical research company reported $0.30 EPS for the quarter, beating analysts' consensus estimates of $0.22 by $0.08. The company had revenue of $638.26 million during the quarter, compared to the consensus estimate of $639.97 million. RadNet had a positive return on equity of 2.61% and a negative net margin of 0.93%. The firm's revenue for the quarter was up 22.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.20 earnings per share. On average, equities research analysts anticipate that RadNet, Inc. will post 0.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Truist Financial increased their price target on shares of RadNet from $90.00 to $94.00 and gave the company a "buy" rating in a research report on Tuesday, August 11th. Raymond James Financial reissued a "strong-buy" rating on shares of RadNet in a report on Tuesday, September 22nd. Zacks Research upgraded shares of RadNet from a "hold" rating to a "strong-buy" rating in a research report on Friday, October 9th. Jefferies Financial Group reaffirmed a "buy" rating on shares of RadNet in a research note on Friday, July 31st. Finally, Barclays upped their price objective on shares of RadNet from $65.00 to $79.00 and gave the company an "overweight" rating in a research note on Friday, August 28th. Three research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $90.00.

RadNet News Summary

Here are the key news stories impacting RadNet this week:

• Positive Sentiment: RadNet reported Q3 EPS of $0.30, beating the $0.22 consensus estimate by 35%. Revenue rose 22.1% year over year to $638.26 million, while the company also reported record quarterly revenue and adjusted EBITDA. RadNet Q3 financial results and revised guidance
• Positive Sentiment: The company raised its 2026 revenue guidance to $2.5 billion–$2.6 billion, versus analyst expectations of about $2.5 billion. This marked its third consecutive quarterly guidance increase. RadNet Q3 earnings and guidance
• Negative Sentiment: Revenue of $638.26 million narrowly missed the $639.97 million consensus estimate, tempering an otherwise strong quarter. RadNet earnings report

About RadNet

RadNet, Inc operates outpatient diagnostic imaging centers in the United States. Its centers provide services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and nuclear medicine imaging.

The company serves patients, physicians and healthcare organizations, with operations across several states, including California, Delaware, Florida, Maryland, New Jersey and New York. Its imaging centers offer diagnostic services for a range of medical needs, from routine screening to specialized examinations.

RadNet also develops digital health and artificial intelligence solutions through its subsidiary DeepHealth, including technology intended to support imaging workflows and assist with image analysis.

Want to see what other hedge funds are holding RDNT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for RadNet, Inc. (NASDAQ:RDNT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.